EpiEndo welcomes Jennifer Kricker, PhD to the team.

EpiEndo has been nominated for the Nordic Life Science Business Class and Deligates choice Awards.

EpiEndo is proud to introduce new external advisers to our Scientific Advisory Board (SAB) and welcome Professors Peter Barnes, Dave Singh and Carl Persson to our team.

EpiEndo is pleased to announce that we have successfully closed a financing round of ISK 110 million (800.000 EUR).

EpiEndo is pleased to welcome Fredrik Lehmann to our team as the new CEO of EpiEndo.

EpiEndo Pharmaceuticals has signed a grant agreement today with the Icelandic Technology Development Fund.

The following were appointed to the board of EpiEndo Pharmaceuticals at the Annual General Meeting on 17 March 2017.

EpiEndo Pharmaceuticals are proud to announce that we have been granted a Horizon 2020 grant from the European Union (EU) for the feasibility of the development of our compounds.

EpiEndo Pharmaceuticals is proud to announce that we have received a 3 year grant from the Technology Development Fund, which is managed by RANNÍS - The Icelandic Centre for Research - and aims to support research and development activities and endorsing innovation in Icelandic technology.